Lumenis Stellar M22
IPL multi-app platform · Updated M22, larger IPL spot
The Lumenis Stellar M22 typically sells new in the $90k–$130k range in the US, with used and refurbished systems around $55k–$85k. Lumenis Stellar M22 holds FDA 510(k) clearance for its marketed indication. Figures are market estimates verified August 6, 2026.
What it's actually cleared for: Modular IPL + laser platform cleared for benign vascular/pigmented lesions, hair removal and inflammatory acne
Last verified: August 6, 2026 · How we verify
New: $90k–$130k|Used: $55k–$85kmarket estimate, no email required
| Manufacturer | Lumenis |
|---|---|
| Company | Owner: Baring Private Equity Asia (BPEA, now part of EQT) (private equity owned, since 2019) · Distribution: direct |
| Category | Hair Removal & IPL |
| Technology | Updated M22, larger IPL spot |
| FDA status | FDA Cleared |
| New price range | $90k–$130k |
| Used price range | $55k–$85k |
| Consumables | Not published |
| Launch year | 2019 |
| Last verified | August 6, 2026 |
Bottom line
The closest thing to a default IPL platform in US dermatology — massive install base, the best-documented IPL science in the category, and a rare non-ablative fractional (ResurFx) with no per-treatment consumable. Not cheap new (low six figures configured with IPL + ResurFx) and Lumenis reps push module bundles hard, but revenue versatility per square foot is excellent. Buy it if IPL photofacials are a core menu item and you want the Photofractional combo story; skip it for hair-removal-only needs. The deep used market lets you enter at half price with acceptable risk.
Overview
Current M22 generation
How it works
The science
Multi-application platform with up to four modules: Universal IPL (515-1200nm broadband), ResurFx (1565nm non-ablative fractional fiber laser), multi-spot long-pulse Nd:YAG 1064nm, and Q-switched Nd:YAG. The IPL uses Optimal Pulse Technology for square, consistent pulses targeting melanin and hemoglobin — sun damage, rosacea, telangiectasias, photoaging. ResurFx creates microscopic dermal coagulation columns for texture, pores, acne scars, striae with minimal downtime. Nd:YAG handles leg veins and deeper vascular lesions. Photofractional is the marketed same-day IPL + ResurFx combo.
Patented tech
OPT is capacitor-controlled square-pulse delivery — energy stays flat across the pulse instead of spiking, why M22 IPL burns less and treats more predictably than cheap IPLs. ExpertFilters: nine snap-in wavelength cutoff filters (515-695nm plus dual-band vascular) tuning one handpiece to different targets and skin types.
Origin
Lumenis Be Ltd., Yokneam, Israel.
FDA & regulatory status
What it's actually cleared for:
Modular IPL + laser platform cleared for benign vascular/pigmented lesions, hair removal and inflammatory acne
510(k) numbers
K193500; K250809
Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.
Recent industry events
How we source company dataOwnership and corporate changes at Lumenis that can affect warranty, service and parts availability.
- Sep 2021
Boston Scientific acquires Lumenis surgical unit for $1.07B
DivestitureBoston Scientific acquired the Lumenis surgical/urology business for $1.07B upfront, announced March 3, 2021 and closed September 1, 2021. The aesthetics and ophthalmology businesses were retained by Baring Private Equity Asia and operate as Lumenis Be Ltd.
Source: Boston Scientific and BPEA press releases
Treatment economics
What practices charge
IPL photofacials $350-600/session, packages of 3 at $900-1,500. ResurFx $500-1,000/session; Photofractional $650-1,200, commonly 3 sessions for $1,800-3,000. Vein/pigment spot treatments $150-400.
Consumables & recurring cost
ResurFx has no consumable tip — a genuine differentiator against Fraxel. IPL costs are flashlamp and sapphire lightguides: ~$1,500-4,000/year for a busy practice, a few dollars per treatment. Filters last years.
Ideal for
Best-fit practice
General medspa or derm practice with a broad menu and Fitzpatrick I-IV clientele — the 35-65 female photoaging demographic is the volume driver. Rewards 15+ IPL treatments weekly; also a strong dry-eye/MGD crossover play (ophthalmology overlap, a real referral channel).
Compliance
Medical director & delegation
Class II prescription device; IPL and non-ablative laser delegable to RNs/aestheticians (state-dependent) under a supervising physician with standing orders — no ablative-tier restrictions.
Contraindications & screening
Recent tanning, isotretinoin within 6 months, photosensitizing meds, pregnancy, active infection or skin cancer in the area, melasma-prone and Fitzpatrick V-VI for IPL (high PIH risk). ResurFx safer in darker types with conservative settings.
Ownership
Warranty & service
1-year standard; extended $8,000-15,000/year by modules. Lumenis US coverage good in metros, slower rurally; third-party service and parts widely available.
Resale & used market
One of the most liquid used aesthetic devices — legacy M22s $25-50k, Stellar units $45-75k by modules and lamp counts. Values stable because IPL demand never fades; verify Lumenis will support a transferred unit.
Chains using this device
No confirmed chain deployments recorded yet.
Owner reviews
Write a reviewNo verified reviews yet — be the first. Founding reviewers get a thank-you gift card for an honest review, positive or negative. How verification works.
Alternatives
History
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Get the full State of Aesthetic Devices 2026 report
The first full census of the US aesthetic device market — preview it free.